Talazoparib for Cohesin-Mutated AML and MDS With Excess Blasts
Talazoparib for Cohesin-Mutated AML and MDS With Excess Blasts
Active, not recruiting · NCT03974217 · Registry updated 2026-02-25Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Talazoparib for Cohesin-Mutated AML and MDS With Excess Blasts | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, hematologic disorder, leukemia, neoplasm | Active, not recruiting | Phase 1 | 2026-02-25 | NCT03974217 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Dana-Farber Cancer Institute | 324 |
| Pfizer | 431 |
2 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Beth Israel Deaconess Medical Center | Boston | United States | 45 |
| Dana Farber Cancer Institute | Boston | United States | 133 |